HR070803

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., The First Affiliated Hospital with Nanjing Medical University

Conditions

Advanced Esophageal CancerEfficacy and Safety

Phase 2

A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Jiangsu HengRui Medicine Co., Ltd.Advanced Esophageal Cancer

Start: 2022-07-27End: 2023-03-30Target: 30Updated: 2022-09-06

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruitingNCT06383078

The First Affiliated Hospital with Nanjing Medical UniversityEfficacy and Safety

Start: 2024-04-20End: 2027-12-30Target: 120Updated: 2024-04-25